Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

A new study suggests that semaglutide, a drug commonly used to treat diabetes, may help protect ... memory function in a well-established mouse model of Alzheimer’s disease.

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

Perspectives from Caroline M. Apovian, MD; Susan P. Mollan, MBChB, FRCOphth, PhD In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic ...

More information: Alan Y. Hsu et al, Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes, JAMA Ophthalmology (2025). DOI: 10.1001/jamaophthalmol.2025.0349 ...

Caviness Distinguished Professor of Medicine and Director of the UNC Diabetes Care Center. “Semaglutide has been a main stay of our efforts to reduce heart attack and stroke in people with diabetes.

But it is an oral version of the GLP-1 analogue that holds the greatest promise for patients with diabetes - and for the company's revenues. Phase 3 trials of injectable semaglutide have shown it ...

Semaglutide is a widely prescribed antidiabetic medicine that acts as a glucagon-like peptide 1 receptor agonist (GLP-1 RA) for the treatment of type 2 diabetes and obesity. A 2024 study by ...

Semaglutide, the medication better known as Ozempic, reduces the symptoms of a condition that can lead to lower limb amputations in people with diabetes, according to a new study that reinforces ...

Although only association and not causality can be inferred, this study showed that, among patients who had diabetes, an elevated risk of NAION was associated with semaglutide use compared with ...